AR100369A1 - Composición de dosis fija de formoterol y budesonide - Google Patents

Composición de dosis fija de formoterol y budesonide

Info

Publication number
AR100369A1
AR100369A1 ARP150101432A ARP150101432A AR100369A1 AR 100369 A1 AR100369 A1 AR 100369A1 AR P150101432 A ARP150101432 A AR P150101432A AR P150101432 A ARP150101432 A AR P150101432A AR 100369 A1 AR100369 A1 AR 100369A1
Authority
AR
Argentina
Prior art keywords
composition
formoterol
budesonide
copd
treatment
Prior art date
Application number
ARP150101432A
Other languages
English (en)
Inventor
Ullmann Michiel
Original Assignee
Teva Pharmaceuticals Europe B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100369(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Europe B V filed Critical Teva Pharmaceuticals Europe B V
Publication of AR100369A1 publication Critical patent/AR100369A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición de dosis fija que comprende formoterol o una sal farmacéuticamente aceptable de él y budesonida, para usar en el tratamiento prolongado de EPOC y el tratamiento de exacerbaciones agudas de EPOC, en donde la composición se administra como una dosis de mantenimiento para el tratamiento prolongado de EPOC y según sea necesario (prn) como una medicación de rescate para el tratamiento de exacerbaciones agudas de EPOC. Reivindicación 2: La composición de la reivindicación 1, caracterizada porque la composición es una formulación de polvo seco, cada una además comprende un portador grueso. Reivindicación 3: La composición de la reivindicación 2, caracterizada porque el portador es lactosa. Reivindicación 4: La composición de la reivindicación 1, caracterizada porque el formoterol está presente como fumarato de formoterol. Reivindicación 7: La composición de las reivindicaciones 5 y 6, caracterizada porque las dosis suministradas de formoterol / budesonida en mg son 80 / 4,5, 160 / 4,5 ó 320 / 9. Reivindicación 12: La composición de cualquiera de las reivindicaciones precedentes, caracterizada porque la composición se administra dos veces por día como una dosis de mantenimiento y no más de ocho veces prn como una medicación de rescate.
ARP150101432A 2014-05-12 2015-05-11 Composición de dosis fija de formoterol y budesonide AR100369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1408387.7A GB201408387D0 (en) 2014-05-12 2014-05-12 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
AR100369A1 true AR100369A1 (es) 2016-09-28

Family

ID=51032625

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150101432A AR100369A1 (es) 2014-05-12 2015-05-11 Composición de dosis fija de formoterol y budesonide
ARP150101431A AR100368A1 (es) 2014-05-12 2015-05-11 Tratamiento de trastornos respiratorios

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP150101431A AR100368A1 (es) 2014-05-12 2015-05-11 Tratamiento de trastornos respiratorios

Country Status (17)

Country Link
US (2) US20170202858A1 (es)
EP (2) EP3142653A1 (es)
JP (4) JP2017515835A (es)
KR (2) KR20170003601A (es)
CN (2) CN106470700A (es)
AR (2) AR100369A1 (es)
AU (2) AU2015261103A1 (es)
BR (2) BR112016026369A2 (es)
CA (2) CA2948574A1 (es)
CL (1) CL2016002848A1 (es)
EA (2) EA201692276A1 (es)
GB (1) GB201408387D0 (es)
IL (2) IL248875A0 (es)
MX (2) MX2016014695A (es)
PE (1) PE20170073A1 (es)
UA (2) UA119774C2 (es)
WO (2) WO2015173154A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758294A (zh) * 2014-12-17 2015-07-08 广州呼吸疾病研究所 用于copd、哮喘治疗的吸入药物组合物及其制备方法
TW201735914A (zh) * 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2018071435A1 (en) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
MX2020008717A (es) * 2018-02-23 2020-12-07 Microdose Therapeutx Inc Inhalador y metodos de uso del mismo.
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613371B1 (en) * 1991-12-18 2002-03-06 AstraZeneca AB New combination of formoterol and budesonide
JP3342484B2 (ja) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) * 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
US20070293460A1 (en) * 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
WO2008021142A2 (en) * 2006-08-09 2008-02-21 Glaxo Group Limited Process for manufacturing lactose
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
RU2010108640A (ru) * 2007-09-12 2011-10-20 Глаксо Груп Лимитед (GB) Новая комбинация терапевтических агентов
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
SI2560611T1 (en) * 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
NZ605920A (en) * 2010-07-16 2015-01-30 Cipla Ltd Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) * 2011-04-08 2012-09-10 Валерий Феофанович Ушаков Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
WO2014007770A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo

Also Published As

Publication number Publication date
UA119773C2 (uk) 2019-08-12
WO2015173153A1 (en) 2015-11-19
CL2016002848A1 (es) 2017-07-07
EA201692278A1 (ru) 2017-02-28
CA2948553A1 (en) 2015-11-19
JP2017515833A (ja) 2017-06-15
WO2015173154A1 (en) 2015-11-19
KR20170003600A (ko) 2017-01-09
GB201408387D0 (en) 2014-06-25
IL248874A0 (en) 2017-01-31
BR112016026371A2 (pt) 2018-06-19
AU2015261103A1 (en) 2016-11-17
JP2020023536A (ja) 2020-02-13
JP2020023537A (ja) 2020-02-13
CA2948574A1 (en) 2015-11-19
MX2016014696A (es) 2017-05-04
IL248875A0 (en) 2017-01-31
BR112016026369A2 (pt) 2018-05-15
AU2015261104A1 (en) 2016-11-17
EA201692276A1 (ru) 2017-03-31
CN106470700A (zh) 2017-03-01
MX2016014695A (es) 2017-05-04
EP3142654A1 (en) 2017-03-22
KR20170003601A (ko) 2017-01-09
CN106488770A (zh) 2017-03-08
US20170209464A1 (en) 2017-07-27
US20170202858A1 (en) 2017-07-20
UA119774C2 (uk) 2019-08-12
EP3142653A1 (en) 2017-03-22
AR100368A1 (es) 2016-09-28
JP2017515835A (ja) 2017-06-15
WO2015173154A9 (en) 2016-03-03
PE20170073A1 (es) 2017-03-24

Similar Documents

Publication Publication Date Title
AR100369A1 (es) Composición de dosis fija de formoterol y budesonide
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
PE20171258A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
CR20160527A (es) Derivados de carboxamida
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson
AR102562A1 (es) Métodos para tratar la enfermedad de huntington usando composiciones de cisteamina
UY35901A (es) Nueva dosificación y formulación
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค

Legal Events

Date Code Title Description
FB Suspension of granting procedure